期刊
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
卷 100A, 期 2, 页码 432-440出版社
WILEY-BLACKWELL
DOI: 10.1002/jbm.a.33228
关键词
hepatocellular; bioresorbable drug delivery system; controlled release; SCPC; cisplatin
Hepatocellular carcinoma (HCC) represents a major global health burden. Typically HCC responds poorly to chemotherapy, and such approaches to treat HCC are commonly associated with severe hepatic and/or systemic toxicity. The aim of this study was to evaluate a porous resorbable silica-calcium phosphate nanocomposite (SCPC) as a controlled release vehicle for cisplatin. Particles of two different formulationsSCPC50 and SCPC75, containing 19.49 and 32.9 mol % silica, respectivelywere loaded with cisplatin by immersion treatment and pressed into discs. In vitro release kinetics studies of cisplatin from SCPC50 and SCPC75 demonstrated an initial burst release of 0.39 +/- 0.04 mg (of the 1.49 mg total loaded) and 0.87 +/- 0.07 mg (of the 2.34 mg total loaded), respectively. Over the following 44-day period. SCPC75-cisplatin hybrid produced a significantly higher sustained cisplatin release than that released from SCPC50. Cisplatin release correlated well with the surface area, and silica dissolution kinetics of the SCPC carrier. Treatment of rat HCC cells (H4IIE) with cisplatin released from SCPC-cisplatin hybrids induced apoptotic cell death in H4IIE cells in vitro. Results of this study suggest that SCPC composites may be of potential use for the treatment of HCC in vivo. (C) 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2012.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据